Hims & Hers Health
HIMS
$32.74
+3.35%
Hims & Hers Health, Inc. operates a telehealth platform connecting patients with healthcare providers for treatments in erectile dysfunction, hair loss, skin care, mental health, and weight loss, offering both prescription and over-the-counter products. As a direct-to-consumer digital health disruptor, it has built a subscriber base of over 2 million and competes by bypassing traditional insurance models. The current investor narrative centers on the company's pivot to weight-loss drugs, which is driving revenue growth but also pressuring near-term profitability, while a recent $350 million convertible debt offering has raised concerns about shareholder dilution and the sustainability of its expansion strategy.…
HIMS
Hims & Hers Health
$32.74
Related headlines
HIMS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $28.42 and implied upside of -13.2% versus the current price.
Average Target
$28.42
0 analysts
Implied Upside
-13.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$21 - $40
Analyst target range
HIMS is covered by 13 analysts, with a consensus recommendation of 'hold' (mean rating 2.8 on a 1-5 scale where 1 is strong buy). The average target price is $28.42, implying a 13.5% downside from the current price of $32.84. The distribution shows 2 buys, 8 holds, and 3 sells, indicating a cautious to bearish sentiment. Recent ratings include a mix of Neutral from BofA, Buy from Canaccord and Needham, and Overweight from Barclays and JP Morgan, suggesting divergence among analysts. The target range spans from a low of $21.00 to a high of $40.00. The high target of $40.00 assumes successful execution on weight-loss drug expansion and margin recovery, while the low target of $21.00 prices in continued profitability challenges and potential dilution from the convertible debt offering. The wide spread of $19.00 between low and high targets reflects high uncertainty about the company's future performance. The recent downgrades and cautious stance from multiple firms underscore the risk, but the presence of several Overweight ratings indicates that some analysts see value at current levels if the company can navigate its transition.
Bulls vs Bears: HIMS Investment Factors
HIMS presents a high-risk, high-reward profile. The bull case rests on the weight-loss drug pivot driving future revenue growth, positive free cash flow, and a low valuation relative to history. However, the bear case is compelling: profitability has collapsed, debt is high, and analyst targets point to downside. The single most important tension is whether the company can return to profitability while sustaining growth—if gross margins stabilize and net income turns positive, the stock could re-rate higher; if losses persist, further dilution and price declines are likely. Currently, the bearish evidence is stronger given the deteriorating fundamentals and cautious analyst sentiment.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew to $608.1M in Q1 2026, up 3.8% YoY, and the forward PS ratio of 1.73 is a 31% discount to the industry average of ~2.5x, suggesting the market underestimates future growth potential from the weight-loss drug pivot.
- Positive Free Cash Flow Generation: HIMS generated $53.0M in free cash flow in Q1 2026 and $75.8M in trailing twelve months, indicating the business can still produce cash despite near-term profitability challenges.
- Strategic Novo Nordisk Partnership: The March 2026 deal with Novo Nordisk removes a major legal overhang and provides a clear growth path for weight-loss drug distribution, which could drive subscriber growth and revenue acceleration.
- Low Valuation Relative to History: The trailing PS ratio of 3.11 is near the low end of its 5-year range of 3x-35x, implying pessimistic expectations are already priced in, offering potential upside if execution improves.
Bearish
- Sharp Profitability Deterioration: Net income swung from a profit of $49.5M in Q1 2025 to a loss of $92.1M in Q1 2026, with net margin falling from 8.4% to -15.1%, driven by gross margin compression from 73.5% to 49.4% due to weight-loss drug costs.
- High Debt and Dilution Risk: Debt-to-equity stands at 2.07, and the recent $350M convertible debt offering threatens significant shareholder dilution, as highlighted by the 10% stock drop in May 2026.
- Analyst Consensus Hold with Downside: With 13 analysts, the consensus is 'hold' (mean rating 2.8) and the average target price of $28.42 implies 13.5% downside from the current $32.84, reflecting cautious sentiment.
- Decelerating Revenue Growth: YoY revenue growth slowed from 16.5% in Q4 2024 to 8.7% in Q2 2025 and further to 3.8% in Q1 2026, indicating the weight-loss drug boost is fading as the base expands.
HIMS Technical Analysis
HIMS is in a broad downtrend, with the stock down 34.3% over the past year compared to the S&P 500's gain of 18.4%. The current price of $32.84 sits at 33.5% of its 52-week range ($13.74 to $70.43), indicating it is closer to the low end, which could suggest a value opportunity but also reflects persistent selling pressure. The 52-week low of $13.74 was set in February 2026, and the stock has recovered 139% from that level, yet remains 53.4% below the 52-week high of $70.43, highlighting the severity of the prior decline. Short-term momentum shows a mixed picture: the 1-month change is +3.0%, while the 3-month change is +13.9%, both positive but lagging the S&P 500's 1-month return of 0.3% and 3-month return of 4.7%. The relative strength over 1 month is 2.7%, outperforming the market, but the 1-year relative strength is -52.7%, indicating a persistent underperformance. This divergence suggests a potential short-term recovery attempt within a longer-term downtrend, but the stock has not yet broken its downward channel. Key support is at the 52-week low of $13.74, while resistance is at the 52-week high of $70.43. A breakout above $70.43 would signal a major trend reversal, while a breakdown below $13.74 could lead to further downside. With a beta of 2.342, HIMS is 134% more volatile than the S&P 500, meaning it amplifies market moves significantly, which is critical for risk management.
Beta
2.34
2.34x market volatility
Max Drawdown
-78.1%
Largest decline past year
52-Week Range
$14-$70
Price range past year
Annual Return
-43.6%
Cumulative gain past year
| Period | HIMS Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +0.6% |
| 3m | +7.1% | +3.4% |
| 6m | +10.5% | +7.1% |
| 1y | -43.6% | +16.4% |
| ytd | -2.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HIMS Fundamental Analysis
Revenue has grown steadily, reaching $608.1 million in Q1 2026, up 3.8% year-over-year from $586.0 million in Q1 2025. However, the growth rate has decelerated from 8.7% YoY in Q2 2025 and 16.5% in Q4 2024, indicating a slowdown. The company's pivot to weight-loss drugs is boosting top-line growth, but the pace is moderating as the base expands. Profitability has deteriorated sharply: net income swung from a profit of $49.5 million in Q1 2025 to a loss of $92.1 million in Q1 2026, with net margin falling from 8.4% to -15.1%. Gross margin also compressed from 73.5% to 49.4% over the same period, reflecting higher cost of revenue from compounded weight-loss drugs and increased marketing spend. The company is now unprofitable after several quarters of positive earnings, raising concerns about its path to sustained profitability. The balance sheet shows elevated leverage: debt-to-equity is 2.07, and the current ratio is 1.90, indicating adequate liquidity but high financial risk. Free cash flow was $53.0 million in Q1 2026, positive but down from $50.1 million in Q1 2025, and the company generated $75.8 million in trailing twelve-month free cash flow. ROE is 23.7%, but this is inflated by the high debt load; the company's reliance on debt financing for expansion, as highlighted by the $350 million convertible offering, increases financial risk.
Quarterly Revenue
$608104000.0B
2026-03
Revenue YoY Growth
+3.8%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$75838000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HIMS Overvalued?
Since net income is negative (Q1 2026 loss of $92.1 million), the trailing PE ratio is not meaningful, so we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 3.11, while the forward PS (based on estimated revenue of $4.21 billion) is approximately 1.73, implying the market expects significant revenue growth. Compared to the healthcare equipment & services industry average PS ratio of around 2.5x (estimated), HIMS trades at a 24% premium on trailing sales, but a 31% discount on forward sales, reflecting high growth expectations. The stock's own historical PS range over the past five years spans from roughly 3x to 35x, with the current trailing PS of 3.11 near the low end of that range. This suggests the market is pricing in pessimistic expectations, potentially due to profitability concerns and competitive pressures in the weight-loss drug market. The forward PS discount to the industry average indicates that if the company can deliver on revenue growth and return to profitability, there could be upside.
PE
57.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 13x~90x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HIMS faces severe profitability pressure, with net income swinging from a $49.5M profit in Q1 2025 to a $92.1M loss in Q1 2026, and gross margin collapsing from 73.5% to 49.4% due to higher cost of revenue from compounded weight-loss drugs. The debt-to-equity ratio of 2.07 is elevated, and the $350M convertible debt offering raises dilution risk, with the company's reliance on debt financing for expansion increasing financial fragility. Revenue growth decelerated to 3.8% YoY, suggesting the weight-loss drug catalyst may be waning, while operating income turned negative at -$16.5M in Q1 2026.
Market & Competitive Risks: The stock trades at a trailing PS of 3.11, a 24% premium to the industry average of ~2.5x, leaving it vulnerable to multiple compression if growth disappoints. With a beta of 2.342, HIMS is highly sensitive to macro conditions, and the recent news of India's generic semaglutide wave threatens to disrupt the weight-loss drug market, potentially eroding HIMS's competitive advantage. The analyst consensus is 'hold' with an average target of $28.42, implying 13.5% downside, reflecting skepticism about the company's ability to navigate competitive and regulatory headwinds.
Worst-Case Scenario: If revenue growth stalls, profitability continues to deteriorate, and dilution from the convertible debt materializes, the stock could fall to its 52-week low of $13.74, representing a 58.2% decline from the current price of $32.84. This scenario would be triggered by a failed execution on the weight-loss drug strategy, increased competition from generics, or a broader market downturn that compresses growth stock multiples further.